Researchers have uncovered a significant mechanism involved in liver fibrosis. Their findings have been published in the journal Gut. The study highlights the extracellular matrix protein 1 (ECM1) as ...
Metabolic dysfunction-associated steatotic liver disease (MASLD)—previously known as "non-alcoholic fatty liver disease"—affects about 25% of the global population. Its severe form, metabolic ...
Cellular senescence is marked by irreversible cell cycle arrest, lysosomal changes, regulatory protein expression, and SASP activation, impacting tissue health and repair. Cellular senescence is a ...
With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic dysfunction-associated non-alcoholic fatty liver disease has become the most prevalent chronic ...
In 1980, Ludwig and colleagues described the histologic features of a newly identified chronic liver condition referred to as nonalcoholic steatohepatitis (NASH) and noted that the majority of the ...
SAN DIEGO — Since the adoption of the most recent Model for End-Stage Liver Disease (MELD 3.0) scoring system by the federal Organ Procurement and Transplantation Network (OPTN) in July 2023, the ...
Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma are increasing in the US. Recent research in hepatocellular carcinoma (HCC) ...
(RTTNews) - Aligos Therapeutics, Inc. (ALGS) has reported recent business progress and outlined continued advancement across its pipeline of drug candidates purpose-built for liver and viral diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results